# Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells

This page is a text version of a Portal Biotechnologies publication. The bibliographic record is labeled in the text so it can be read without the surrounding website.

## Bibliographic record

- Title: Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells
- Document type: Publication
- Year: 2017
- Outlet: ACS CHEMICAL BIOLOGY
- Cells: PBMCs, T cells, Monocytes, NK cells, B cells
- Cargos: Polymers, small molecules
- Page URL: https://portal.bio/publications/2017-microfluidic-enabled-intracellular-delivery-of-membrane-impermeable-inhibitors-to-stu--ajkHLREAACcAc-DP
- Markdown URL: https://portal.bio/publications/2017-microfluidic-enabled-intracellular-delivery-of-membrane-impermeable-inhibitors-to-stu--ajkHLREAACcAc-DP.md
- External publication: https://pubs.acs.org/doi/abs/10.1021/acschembio.7b00683

## Summary

Jing Li, Bu Wang, Brian M. Juba, Michael Vazquez, Steve W. Kortum, Betsy S. Pierce, Michael Pacheco, Lee Roberts, Joseph W. Strohbach, Lyn H. Jones, Erik Hett, Atli Thorarensen, Jean-Baptiste Telliez, Armon Sharei, Mark Bunnage, and Jonathan Brian Gilbert

## Publication text

Portal does not host the full text of this publication. The summary on this page and the external publication are the available sources.

## Provenance

Some publications reference SQZ Biotechnologies, a company Dr. Armon Sharei and colleagues previously founded. Portal is the next generation company leveraging Dr. Sharei's platform technology.